Praesidian Capital Successfully Exits Investment in Biologos
OKLAHOMA CITY, March 21, 2024 /PRNewswire/ -- Praesidian Capital, a private equity firm headquartered in Oklahoma City with offices in New York and London, announced the successful exit of its investment in Biologos Holdings, LLC ("Biologos"), a provider of sterile-filtered biological products for veterinary, pharmaceutical, and medical research applications.
Praesidian made an initial investment in Biologos in 2015 through its fifth investment fund, Praesidian Capital Bridge Fund, LP.
"We are proud to have been a part of Biologos' journey and are pleased with the successful outcome of the investment," commented Jason Drattell, Praesidian Founder. "The Company's dedication to providing superior products has solidified its position as a trusted leader in its field."
About Praesidian Capital
Praesidian Capital is an innovative private investment firm focused on control investments in private lower middle market businesses in the United States, United Kingdom, Germany, and selectively in Northern Europe. For more information, visit www.praesidian.com.
To discuss prospective investment opportunities please contact:
Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where's Crohn's & Colitis (CC)? campaign for this year's World IBD Day (19 May 2024).
The campaign focuses on access to IBD care and treatment as the burden of...
On Wednesday, May 15, Red Door Community hosted their annual Celebrating Women Working and Living with Cancer Luncheon at the Metropolitan Club in New York City. The event raised more than $300,000 while shining a light on the women who inspire us...
Product: Kalihim (Philippine Bread Roll)
Issue: Food - Allergen - Egg
Distribution: British Columbia
See the affected products and product photos for this recall
SOURCE Canadian Food Inspection Agency (CFIA)
The global industrial automation market in life sciences industry size is estimated to grow by USD 5.06 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 11.4% during the forecast period. ...
Boston Scientific Corporation today announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRMtm System,* the first modular cardiac rhythm management (CRM) system that consists of the EMBLEMtm Subcutaneous...
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...